TMO · Thermo Fisher Scientific Inc.
$627.53
-1.21 (-0.19%)
At close · Aug 25
Market Cap
$232.47B
Shares
369.75M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$44.56B
+3.9%
FY2025
Net Income
$6.7B
+5.8%
FY2025
Gross Margin
57.09%
+2pp
FY2017
Operating Margin
17.38%
+0.3pp
FY2025
Diluted EPS
$17.74
+7.3%
FY2025
Operating Cash Flow
$7.82B
-9.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $47.4B – $48.1B | $46.34B | $44.56B | $42.88BG | $42.86BG | $44.92B | $39.21B | $32.22B | $25.54B | $24.36B | $20.92B | $18.27B | $16.97B | $16.89B | $13.09B | $12.51B | $11.56B | $10.39B | $9.91B | $10.5B | $9.75B | |
| — | $9.17B | — | — | — | — | — | — | — | — | $8.98B | $8.21B | $7.58B | $7.93B | $6.31B | $6.1B | $5.73B | $5.26B | $5.16B | $5.3B | $5.08B | |
| — | $12.83B | — | — | — | — | — | — | — | — | $11.94B | $10.06B | $9.38B | $8.95B | $6.78B | $6.41B | $5.83B | $5.13B | $4.76B | $5.2B | $4.67B | |
| — | — | — | — | — | — | — | — | — | — | 57.09% | 55.05% | 55.3% | 53.02% | 51.8% | 51.23% | 50.4% | 49.34% | 47.98% | 49.52% | 47.89% | |
| — | $1.4B | $1.4B | $1.39B | $1.34B | $1.47B | $1.41B | $1.18B | $1B | $967M | $887M | $754M | $692M | $691.1M | $395.5M | $376.4M | $340.2M | $284.4M | — | — | — | |
| — | $9.03B | $8.73B | $8.6B | $8.45B | $8.99B | $8.01B | $6.93B | $6.14B | $6.06B | $5.5B | $4.97B | $4.61B | $4.9B | $3.45B | $3.35B | $3.11B | $2.73B | $2.59B | $2.69B | $2.55B | |
| — | — | $1.73B | $1.95B | $2.34B | $2.4B | $1.76B | $1.67B | $1.71B | $1.74B | $1.59B | $1.38B | $1.31B | $1.33B | $763.1M | $747.6M | $647.9M | $554.7M | $579.9M | $602.8M | — | |
| — | — | — | — | — | — | — | — | — | $2.27B | $2.03B | $1.76B | $1.69B | $1.68B | $999.9M | $983.7M | $859.6M | $739.7M | $762.9M | $792.7M | $756.8M | |
| — | — | $197M | $97M | $194M | $68M | $37M | $51M | $52M | $88M | $106M | $167M | $90M | $253.7M | $81M | — | — | — | — | — | — | |
| — | $38.19B | $36.81B | $35.54B | $36B | $36.52B | $29.18B | $24.42B | $20.95B | $20.58B | $17.96B | $15.82B | $14.63B | $14.39B | $11.48B | $11.03B | $10.31B | $9.21B | $8.91B | $9.27B | $8.77B | |
| — | $8.15B | $7.75B | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B | $4.59B | $3.78B | $2.96B | $2.46B | $2.34B | $2.5B | $1.61B | $1.48B | $1.25B | $1.19B | $1B | $1.23B | $974.4M | |
| — | — | 17.38% | 17.11% | 16% | 18.69% | 25.57% | 24.19% | 17.99% | 15.53% | 14.15% | 13.45% | 13.77% | 14.82% | 12.3% | 11.85% | 10.82% | 11.43% | 10.11% | 11.71% | 10% | |
| — | — | — | — | — | — | — | — | — | $6.05B | $4.99B | $4.22B | $4.02B | $4.19B | $2.61B | $2.47B | $2.11B | $1.93B | $1.77B | $2.02B | $1.73B | |
| — | $1.47B | $1.42B | $1.39B | $1.38B | $726M | $536M | $553M | $676M | $667M | $592M | $469M | $415M | $479.9M | $262.1M | $241.6M | $175.3M | $84.7M | $118M | $151.5M | — | |
| — | $1.02B | $993M | $1.08B | $879M | $272M | $43M | $65M | $224M | $137M | $81M | $48M | $31M | $47.7M | $28M | $25.2M | $26.8M | $12.4M | $16.1M | $51.7M | — | |
| — | -$24M | -$12M | $12M | -$65M | -$104M | -$694M | -$76M | -$70M | $9M | -$20M | -$13M | -$16M | $16.4M | -$56M | $3.7M | $30.5M | -$28.1M | -$19.8M | $4M | — | |
| — | -$52M | -$41M | -$42M | -$59M | -$172M | -$4M | -$3M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $37M | $13M | $21M | -$46M | -$161M | $66M | $10M | $44M | -$15M | $17M | $13M | — | $9M | $5M | — | — | $1.2M | -$3.1M | -$5.6M | — | |
| — | $7.64B | $7.31B | $7.04B | $6.3B | $7.84B | $8.84B | $7.23B | $4.07B | $3.26B | $2.43B | $2.02B | $1.94B | $2.09B | $1.32B | $1.27B | $1.13B | $1.09B | $880.4M | — | — | |
| — | $597M | $547M | $657M | $284M | $703M | $1.11B | $850M | $374M | $324M | $201M | -$1M | -$44M | $191.7M | $40.4M | $11M | $109.4M | $101.6M | $57.2M | $152.6M | $93.7M | |
| — | $6.97B | $6.7B | $6.34B | $6B | $6.96B | $7.73B | $6.38B | $3.7B | — | — | — | — | — | $1.27B | $1.18B | $1.33B | $1.04B | $850.3M | $980.9M | $748.4M | |
| — | — | 15.05% | 14.77% | 13.99% | 15.5% | 19.71% | 19.79% | 14.48% | — | — | — | — | — | 9.73% | 9.42% | 11.51% | 9.96% | 8.58% | 9.34% | 7.68% | |
| — | $21M | $17M | $3M | -$40M | $10M | $3M | $2M | $2M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $6.51B | — | $6.34B | $6B | $6.95B | $7.73B | $6.38B | $3.7B | $2.94B | $2.23B | $2.02B | $1.98B | $1.89B | $1.27B | $1.18B | — | — | — | — | — | |
| — | $7.3B | $6.95B | $6.86B | $5.87B | $6.18B | $8.2B | $6.25B | $3.52B | $2.53B | $2.86B | $1.38B | $1.26B | $686.6M | $1.35B | $1.43B | $886.8M | $987.2M | $1.09B | $446.7M | $986.6M | |
| USD/shares | — | — | $17.77 | $16.58 | $15.52 | $17.75 | $19.62 | $16.09 | $9.24 | $7.31 | $5.64 | $5.12 | $4.96 | $4.76 | $3.53 | $3.24 | $3.49 | $2.57 | $2.06 | $2.34 | $1.77 |
| USD/shares | $24.93 – $25.33* | — | $17.74 | $16.53G | $15.45G | $17.63 | $19.46 | $15.96 | $9.17 | $7.24 | $5.59 | $5.09 | $4.92 | $4.71 | $3.48 | $3.21 | $3.46 | $2.53 | $2.01 | $2.25 | $1.69 |
| shares | — | — | 377M | 382M | 386M | 392M | 394M | 396M | 400M | 402M | 395M | 395M | 399M | 398.2M | 360.3M | 363.8M | 380.8M | 403.3M | 412.4M | 418.2M | 421.5M |
| shares | — | — | 378M | 383M | 388M | 394M | 397M | 399M | 403M | 406M | 398M | 397M | 402M | 402.3M | 365.8M | 366.6M | 384.8M | 409.4M | 422.8M | 434.7M | 443.6M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $26.09B in buybacks, $4.8B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
5.85×
Peer median 6.61×
EV/EBIT
33.26×
Peer median 28.86×
P/E (TTM)
33.82×
Peer median 31.80×
Peer medians compare against the 10 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | $23,984,000,000 | $23,157,000,000 | $23,041,000,000 | — | — | — | — | — |
| Life Sciences Solutions | $10,374,000,000 | $9,631,000,000 | $9,977,000,000 | $11,565,000,000 | $15,631,000,000 | $12,168,000,000 | $6,856,000,000 | $6,269,000,000 |
| Analytical Instruments | $7,554,000,000 | $7,463,000,000 | $7,263,000,000 | $6,441,000,000 | $6,069,000,000 | $5,124,000,000 | $5,522,000,000 | $5,469,000,000 |
| Specialty Diagnostics | $4,676,000,000 | $4,512,000,000 | $4,405,000,000 | $4,604,000,000 | $5,659,000,000 | $5,343,000,000 | $3,718,000,000 | $3,724,000,000 |
| Laboratory Products and Services | — | $23,002,000,000 | $22,888,000,000 | $22,304,000,000 | $14,862,000,000 | $12,245,000,000 | $10,599,000,000 | $10,035,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| North America | $23,033,000,000 | $22,504,000,000 | $22,764,000,000 | $24,594,000,000 | $19,659,000,000 | $17,081,000,000 | $12,896,000,000 | $12,143,000,000 |
| Europe | $11,826,000,000 | $10,857,000,000 | $10,741,000,000 | $10,762,000,000 | $11,134,000,000 | $8,284,000,000 | $6,358,000,000 | $6,215,000,000 |
| Asia Pacific | $8,101,000,000 | $7,956,000,000 | $7,873,000,000 | $8,115,000,000 | $7,218,000,000 | $5,822,000,000 | $5,524,000,000 | $5,250,000,000 |
| Other Regions | $1,597,000,000 | $1,561,000,000 | $1,479,000,000 | $1,444,000,000 | $1,200,000,000 | $1,031,000,000 | $764,000,000 | $750,000,000 |
| China | — | — | — | $3,793,000,000 | $3,444,000,000 | — | — | — |
| United States | — | $21,755,000,000 | $22,013,000,000 | $23,820,000,000 | $18,907,000,000 | — | — | — |
| All Other Countries | — | $21,124,000,000 | $20,844,000,000 | $21,095,000,000 | $20,304,000,000 | — | — | — |
| Non Us | — | $21,124,000,000 | $20,844,000,000 | — | — | — | — | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $25,965,000,000 | $25,034,000,000 | $25,243,000,000 | $28,548,000,000 | $30,361,000,000 | $25,306,000,000 | $19,496,000,000 | $18,868,000,000 |
| Consumables | $18,664,000,000 | $17,587,000,000 | $17,597,000,000 | $20,624,000,000 | $22,608,000,000 | $18,527,000,000 | $13,109,000,000 | $12,576,000,000 |
| Service | $18,592,000,000 | $17,845,000,000 | $17,614,000,000 | $16,367,000,000 | $8,850,000,000 | $6,912,000,000 | $6,046,000,000 | $5,490,000,000 |
| Instruments | $7,301,000,000 | $7,446,000,000 | $7,646,000,000 | $7,924,000,000 | $7,753,000,000 | $6,779,000,000 | $6,387,000,000 | $6,292,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Life Sciences Solutions | $3,768,000,000 | $3,503,000,000 | $3,420,000,000 | $5,582,000,000 | $7,817,000,000 | $6,109,000,000 | $2,446,000,000 | $2,158,000,000 |
| Laboratory Products and Biopharma Services | $3,350,000,000 | $3,090,000,000 | $3,358,000,000 | — | — | — | — | — |
| Analytical Instruments | $1,736,000,000 | $1,955,000,000 | $1,908,000,000 | $1,507,000,000 | $1,197,000,000 | $808,000,000 | $1,273,000,000 | $1,247,000,000 |
| Specialty Diagnostics | $1,256,000,000 | $1,159,000,000 | $1,124,000,000 | $1,024,000,000 | $1,280,000,000 | $1,368,000,000 | $930,000,000 | $952,000,000 |
| Laboratory Products and Services | — | $3,090,000,000 | $3,358,000,000 | $2,872,000,000 | $1,844,000,000 | $1,271,000,000 | $1,324,000,000 | $1,258,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | 14% | 13.3% | 14.6% | — | — | — | — | — |
| Life Sciences Solutions | 36.3% | 36.4% | 34.3% | 48.3% | 50% | 50.2% | 35.7% | 34.4% |
| Analytical Instruments | 23% | 26.2% | 26.3% | 23.4% | 19.7% | 15.8% | 23.1% | 22.8% |
| Specialty Diagnostics | 26.9% | 25.7% | 25.5% | 22.2% | 22.6% | 25.6% | 25% | 25.6% |
| Laboratory Products and Services | — | 13.4% | 14.7% | 12.9% | 12.4% | 10.4% | 12.5% | 12.5% |
Key facts
CIK
97745
CUSIP
883556102
13F (30d)
1897 filings
1826 filers
Visit website
Investor relations